**EASDEC 2011 Programme**

**13th May 2011: Friday**

**Satellite 1:**
12.30–4.45: Screening for Diabetic Retinopathy in Europe - Strategies for Overcoming Hurdles to Progress
Organising Committee: Professor Simon Harding, Dr Deborah Broadbent, Dr Kenneth Swa, Professor Elzbieta Bandurska-Stankiewicz

**Satellite 2:**
4.45–6.00: Novartis symposium: Ranibizumab in DME – new age of treatment
Chaired by: Professor Krystina Raczynska and Professor Anne Katrin Sjølie
Dr Malukiewicz: Diabetic macular oedema – epidemiology and social issue
Dr Partyka: Diagnostic and current methods of treatment of DME
Dr Robaszkiewicz: Lucentis in DME

7.15: Opening ceremony followed by refreshments

**14th May 2011: Saturday**

8.30–9.15: Registration
9.15–Introduction and welcome Anne Katrin Sjølie and Elzbieta Bandurska Stankiewicz

**Session 1: Combined session with the European Hypertension Society**
Chairs: Krysztof Narkiewicz and Massimo Porta
9.20–9.50: Invited lecture: Roland E Schmieder: Vascular remodelling of the microcirculation in hypertension and diabetes
9.50–10.05: Possible role of angiotensin II receptor blockade in the glucotoxicity on human retinal pericytes. E. Berrone, E. Beltramo, S. Tarallo, M. Porta

10.50–11.20: Coffee/tea, exhibitions

**Session 2: Combined session with the European Hypertension Society**
Chairs: Tunde Peto and Elisabet Agardh
11.20–11.50: Invited lecture: Enrico Agabiti Rosei: Treatment of hypertensive diabetic patients: the goals and strategies

11.50–12.05: The predictive power of microaneurysm count on development of sight threatening retinopathy and the response to treatment with an angiotensin receptor blocker. Results from the DIRECT Programme. A.K. Sjølie for the DIRECT Programme Study Group

12.05–12.20: Deterioration of the glomerular filtration rate and high vascular endothelial growth factor level in the eye are seemed to be the markers of diabetic retinopathy progression after cataract surgery. A.G. Kuzmin, D.V. Lipatov, T.A. Chistyakov, O.M. Smirnova, M.I. Arbusova, A.V. Ilyin, M.V. Shestakova

12.20–12.35: Risk factors for diabetic eye complications in short duration (1-10 years) of type 1 diabetes in Warmia and Mazury, Poland. J. Pieczynski, E. Bandurska-Stankiewicz, W. Matuszewski, J. Rutkowska, D. Wiatr-Bykowska


12.50–1.45: Lunch and Exhibition viewing

1.45–2.45: Session 3: Poster session

Chairs: Stela Vujosevic and Grazyna Malukiewicz

A new system for screening of diabetic retinopathy in institute for clinical and experimental medicine (IKEM). T. Sosna, R. Svancarova, M. Kahle

Changes in vascular diameter after laser treatment in patients with diabetic macular edema. K. Lundberg, A.K. Sjølie, J. Grauslund

Diabetes is associated with changes in retinal vessel calibre in women. T. von Hanno, G. Bertelsen, J. Grauslund, A.K. Sjølie, E.B. Mathiesen

No difference in prevalence of retinal vein occlusions (RVO) between diabetic and non diabetic participants in The Tromsø Eye Study. G. Bertelsen, M.G. Erke, A.K. Sjølie, I. Njølstad

British Ophthalmic Surveillance Unit (BOSU) study of Progression to Sight Threatening Retinopathy in Pregnancy (STDR). C. Mulholland, M. Quinn, W. Chan, B. Foot

Management and Outcome of Cholesterol Embolus Identified in a Diabetic Retinopathy Screening Programme. K. Whitehouse, P.M. Dodson

Does long chain polyunsaturated fatty acids (PUFA) protect against diabetic retinopathy? K. E. Alsbirk, J. H. Seland

Diabetic retinopathy prevalence in patients with short duration (1-10 years) of type 1 diabetes in Warmia and Mazury region, Poland. J. Pieczynski, E. Bandurska-Stankiewicz, W. Matuszewski, J. Rutkowska, D. Wiatr-Bykowska

Evaluation of the effectiveness of surgical treatment of idiopathic macular holes using optical coherence tomography. M. Gorczyca, S. Zalewski

Posterior vitrectomy in the ophthalmology unit of general district hospital in Olsztyn, Poland. J. Pieczynski, E. Bandurska-Stankiewicz, W. Matuszewski

Prevalence and incidence of diabetic macular edema in the pediatric population. M. B. Sultan, C. Starita, K. Huang

How accurate are photographic surrogate markers used to detect macular oedema in the English National Screening Programme? H.M. Wharton, J.M. Gibson, P.M. Dodson
Pre-eclampsia is not a predictor of progression of diabetic retinopathy. M. Lind, A. K. Sjølie

2.45–3.10: Coffee break

Session 4: Risk factors
Chairs: Simon Harding and Elżbieta Bandurska-Stankiewicz
3.10–3.30: Deborah Broadbent: Report to Conference: Screening for diabetic retinopathy in Europe/Strategies for overcoming hurdles to progress
3.30–3.45: Cardiovascular disease and mortality are related to which vision threatening complication that develops in type 2 diabetic patients. K. Tilma, T. Bek
4.00–4.45: Eva Kohner lecture: Irene Stratton: Does high blood pressure matter in DR? A review of evidence old and new

4.45–5.00: Annual General Meeting
Gala dinner: 7.30 for 8.00 at the Maritime Museum

15th May 2011, Sunday

Session 5: Pathophysiology of diabetic retinopathy
Chairs: Edoardo Midena and Toke Bek
9.00–9.30: Invited lecture: Rafael Simo: Neurodegeneration as an early event of diabetic retinopathy: therapeutic implications
10.15–10.30: The impact of diabetes on the characteristics of Type 2 Macular Telangiectasia. T. Peto, T.E. Clemons, F.B. Sallo, I. Leung

10.30–11.00: Coffee break

Session 6: Screening and prevention
Chairs: Francesco Bandello and Krystina Raczynska
11.00–11.30: Invited lecture: Jan Taton: Prevention and rehabilitation of significant vision impairment with diabetes mellitus
11.45–12.00: Late Breaking News Abstract
12.00–12.15: Proliferative diabetic retinopathy (R3) referrals from the digital diabetic retinopathy screening program: Urgency of appointment in the hospital eye service achieved and needed? T. K. Geletew, P.M. Amrelia, H.M. Wharton, P.M. Dodson, J.M. Gibson, A. Wright

12.15: Awarding the best poster prize
12.20: Close of meeting